Sivaneswary Genapathy
Associate Director
Bicycle Therapeutics
Talk Information
Peptides in Oncology
18 June 2025, 11:25am - 11:50am, in the Pacific Jewel Ballroom
L43 – Bicycle® Molecules as an Innovative and Unique Therapeutic Class
Academic Background
Dr. Siva Genapathy studied pharmacy and completed her pre-registration training at GlaxoSmithKline and the Princess Alexandra Hospital NHS Trust. She went on to earn a Ph.D. in pharmacy from the University of Nottingham, specialising in peptide therapeutics. Her research focused on the development of antibacterial peptides, underpinning a long-standing interest in the intersection of molecular design and therapeutic application.
Professional Background
Dr. Genapathy is an Associate Director and Project Leader at Bicycle Therapeutics where her focus is advancing Bicycle Radio Conjugates into clinical development. Prior to joining Bicycle Therapeutics, she spent 9 years at AstraZeneca where she worked across multiple therapeutic areas including metabolism, oncology, and rare diseases. She led the development of an innovative platform to accelerate hit-to-lead optimization using advanced mass spectrometry. She works closely with multidisciplinary teams to translate early-stage research into clinical candidates, using both traditional and emerging technologies in peptide engineering.
Notable Contributions
Dr. Genapathy is the lead inventor of two clinical-stage peptide therapeutics and has contributed to several high-impact programs at Bicycle Therapeutics and AstraZeneca. Her collaborative and cross-disciplinary work has driven innovation in peptide drug discovery and development.
Professional Engagements
As a member of the UK Young Academy, Dr. Genapathy is actively involved in knowledge exchange and mentoring initiatives. She contributes to professional networks and symposia that promote innovation in peptide science and the advancement of precision medicine. Her industry perspective adds depth to ongoing conversations about the future of peptide-based therapeutics and their role in precision medicine. Through her industry-based research, cross-disciplinary collaborations, and commitment to scientific advancement, Dr. Genapathy continues to contribute meaningfully to the evolution of peptide therapeutics in modern medicine.
Bicycle® Molecules as an Innovative and Unique Therapeutic Class
Bicycle Therapeutics, Cambridge, United Kingdom
Bicycle® molecules are a novel molecule formed by constraining short linear peptides into a stabilized bi-cyclic structure using a central chemical scaffold. Bicycle molecules have a unique structure that can deliver high precision to their chosen targets, while their size and surface area means they can potentially engage targets that have historically been resistant to conventional modalities.
Bicycle molecules can be readily conjugated to other payloads, such as Bicycle Drug Conjugates containing a selectively cleavable linker and a small molecule toxin payload, and Bicycle Radionuclide Conjugates® containing a stable linker-chelator system and a highly potent radioisotope.
They are designed to address significant unmet medical needs in patients.